Associated Genetic Biomarkers
EZH2 Y646C is a predictive biomarker for use of tazemetostat in patients.
Of the therapies with EZH2 Y646C as a predictive biomarker, 1 is FDA-approved in at least one clinical setting.
Follicular lymphoma has the most therapies targeted against EZH2 Y646C or its related pathways .
Follicular Lymphoma -
|Biomarker Criteria:||Predicted Response: Primary Sensitivity|
|Clinical Setting(s): Refractory (FDA), Relapse (FDA)|
|Note: Indicated for adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation and who have received at least 2 prior systemic therapies.|
Significance of EZH2 Y646C in Diseases
Follicular Lymphoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.